Sees FY26 revenue $1.055B-$1.115B, consensus $1.04B. Sees FY26 adjusted EBITDA $275M-$290M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
- ANI Pharmaceuticals issues strong 2025 preliminary results, 2026 outlook
- ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
- ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’